Efficacy of imiquimod in solitary plaques of mycosis fungoides

International Journal of Tissue Reactions

Volumn 27, Issue 4, 2005, Pages 167-172

  Onsun, Nahide ^a,b   Ufacik, H ^a   Kural, Y ^a   Topcu E ^a   Somay, A ^a  

^a VAKIF GUREBA HOSPITAL   (Turkey)

^b Sezai Selek Sok   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; CORTICOSTEROID; IMIQUIMOD; STEROID;

ADULT; ARTICLE; CASE REPORT; CONTACT DERMATITIS; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MYCOSIS FUNGOIDES; PHYSICAL EXAMINATION; SACRUM; SCALP; SKIN ATROPHY; SKIN BIOPSY; SKIN MANIFESTATION;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; MYCOSIS FUNGOIDES;

EID: 30344447511     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Willemze R., Kerl H., Sterry W., et al. EORTC classification for primary cutaneous lymphomas a proposal from the cutaneous lymphoma group of the European Organisation for Research and Treatment of Cancer. Blood, 90, 354, 1997.
2. Lutzner M., Edelson R., Schein P., et al. Cutaneous T cell lymphomas: The Sézary syndrome, mycosis fungoides and related disorders. Ann. Intern. Med., 83, 534, 1975.
3. Dummer R., Heald P.W., Nestle F.O., et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood, 88, 1383, 1996.
4. Mosmann T., Cherwinski H., Bond M.W., et al. Two types of murine helper T cell clone I: Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol., 136, 2348, 1986.
5. Zackheim H.S., Amin S., Kashani-Sabet M., et al. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J. Am. Acad. Dermatol., 40, 418, 1999.
6. Berger C.L., Wang N., Christensen I., et al. The immune response to class I associated tumor-specific cutaneous T-cell lymphoma antigens. J. Invest. Dermatol., 107, 392, 1996
7. + cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor lysis. J. Invest. Dermatol., 115, 74, 2000.
8. Apisarntharanax N., Duvic M. Cutaneous T cell lymphoma. New immunomodulators. Dermatol. Clin., 19, 737, 2001.
9. Wagner T.L., Ahonen C.L., Conture A.M., et al. Modulation of TH1 and TH2 cytokine production with the immun modifiers R- 848 and imiquimod. Cell Immunol., 191, 10, 1999.
10. Sauder D.N. Immunomodulatory and pharmacologic properties of imiquimod. J. Am. Acad. Dermatol., 43(1 pt. 2S, S6), 2000.
11. Beutner K.R., Geisse J.K., Helman D., et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J. Am. Acad. Dermatol., 41, 1002, 1999.
12. Ahmed I., Berth-Jones J. Imiquimod; a novel treatment for lentigo maligna. Br. J. Dermatol., 143, 843, 2000.
13. Steinmann A., Funk J.D., Schuler G., et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J. Am. Acad. Dermatol., 43, 555, 2000
14. Stockfleth E., Meyer T., Benninghof B., et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch. Dermatol., 138, 1498, 2002.
15. Suchin K.R., Junkins-Hopkins J., Rook A.H. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier. Arch. Dermatol., 138, 1137, 2002.